Latest news

• India could hit Roche and BMS with compulsory licences

  Sprycel (dasatinib) and its chemotherapy Ixempra (ixabepilone).

• Paclitaxel tops newer drugs in comparative breast cancer study

  nab] paclitaxel) and 7.6 months with Bristol-Myers Squibb's Ixempra (ixabepilone) in the cohort of chemotherapy-naïve patients. ... Ixabepilone was significantly inferior to paclitaxel [and] nab-paclitaxel was not superior to paclitaxel in this

• Triple negative breast cancer

  One compound that works via this method is ixabepilone, which binds tubulin and promotes tubulin stabilisation whereby cell division cannot be completed. ... Bristol-Myers Squibb is also investigating ixabepilone in combination with cetuximab in the

• Eisai wins approval for breast cancer drug

  and with Bristol-Myers Squibb's Ixempra (ixabepilone), which is marketed for patients with late- stage disease after failure of an anthracycline, taxane and Xeloda.

• Bristol-Myers signs cancer drug deal

  BMS' existing cancer-drug portfolio includes Erbitux (cetuximab), Ixempra (ixabepilone) and Sprycel (dasatinib).